Clinical Trial Update: Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the neuromodulatory effects of ketamine in individuals with Long COVID and is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: University of Texas at Austin | Conditions: Long COVID | Phase 2 | Status: ENROLLING_BY_INVITATION